391 related articles for article (PubMed ID: 24006505)
1. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
3. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
[TBL] [Abstract][Full Text] [Related]
5. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
[TBL] [Abstract][Full Text] [Related]
6. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
7. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy of non-small cell lung cancer: Tolerance of combined cisplatin-pemetrexed therapy].
Gauvain C; Crequit P; Rousseau-Bussac G; Ganoun A; Baud M; Chouaid C
Rev Mal Respir; 2014 Nov; 31(9):817-21. PubMed ID: 25433586
[TBL] [Abstract][Full Text] [Related]
11. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
[TBL] [Abstract][Full Text] [Related]
15. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
16. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.
Kreuter M; Vansteenkiste J; Griesinger F; Hoffmann H; Dienemann H; De Leyn P; Thomas M
BMC Cancer; 2007 May; 7():77. PubMed ID: 17488518
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
18. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
19. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer.
Tachihara M; Dokuni R; Okuno K; Tokunaga S; Nakata K; Katsurada N; Yamamoto M; Nagano T; Kobayashi K; Tanaka Y; Funada Y; Maniwa Y; Nishimura Y
Thorac Cancer; 2020 Sep; 11(9):2536-2541. PubMed ID: 32729237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
